GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (STU:PHPN) » Definitions » Float Percentage Of Total Shares Outstanding

Galectin Therapeutics (STU:PHPN) Float Percentage Of Total Shares Outstanding : 48.01% (As of Jun. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Galectin Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Galectin Therapeutics's float shares is 29.84 Mil. Galectin Therapeutics's total shares outstanding is 62.15 Mil. Galectin Therapeutics's float percentage of total shares outstanding is 48.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Galectin Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Galectin Therapeutics's Institutional Ownership is 6.03%.

Galectin Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Galectin Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=29.84/62.15
=48.01%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics (STU:PHPN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (STU:PHPN) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
OBIO CAPR YS BLUE PBYI ACHV OMER OTLK ZVRA ATOS OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
GALT:USA
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Website
https://www.galectintherapeutics.com
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics (STU:PHPN) Headlines

No Headlines